CVnCoV Vaccine

BIOLOGICAL4 trials

Sponsors

CureVac

Conditions

COVID-19CoronavirusCovid19SARS-CoV-2Severe Acute Respiratory Syndrome

Phase 1

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

CompletedNCT04449276

CureVacCoronavirus, COVID-19, SARS-CoV-2 +1

Start: 2020-06-18End: 2021-12-21Updated: 2023-01-30

Phase 3

A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19

CompletedNCT04674189

CureVacCoronavirus, Covid19, SARS-CoV-2 +1

Start: 2020-12-23End: 2022-06-08Updated: 2023-10-06

A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19

WithdrawnNCT04838847

CureVacCoronavirus, Covid19, SARS-CoV-2 +1

Start: 2021-10-01End: 2022-09-30Updated: 2021-08-20

COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities

TerminatedNCT04860258

CureVacCoronavirus, Covid19, SARS-CoV-2 +1

Start: 2021-04-22End: 2021-09-21Updated: 2022-05-13

Related Papers

A phase 3, randomised, observer-blinded, placebo controlled-trial evaluating the safety and immunogenicity of investigational SARS-CoV-2 mRNA vaccine CVnCoV in adult healthcare workers in Mainz (Germany)

Vaccine X2024-06-20

Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial.

2021-01-22138 citations